Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.007 AUD | 0.00% | +16.67% | -22.22% |
Apr. 16 | OncoSil Medical Treats First Commercial Patient in Turkey with Implantable Pancreatic Cancer Device | MT |
Apr. 12 | OncoSil Medical Treats First UK Patient for Pancreatic Cancer Study | MT |
Sales 2022 | 1.06M 684K | Sales 2023 | 1.47M 945K | Capitalization | 23.71M 15.26M |
---|---|---|---|---|---|
Net income 2022 | -10M -6.44M | Net income 2023 | -11M -7.08M | EV / Sales 2022 | 27 x |
Net cash position 2022 | 10.98M 7.06M | Net cash position 2023 | 9.22M 5.94M | EV / Sales 2023 | 9.87 x |
P/E ratio 2022 |
-3.02
x | P/E ratio 2023 |
-1.2
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 55.27% |
1 week | +16.67% | ||
Current month | +40.00% | ||
3 months | -12.50% | ||
6 months | -12.50% | ||
Current year | -22.22% |
Managers | Title | Age | Since |
---|---|---|---|
Nigel Lange
CEO | Chief Executive Officer | - | 20-05-03 |
Christian Cin
DFI | Director of Finance/CFO | - | 23-05-31 |
Jon Bell
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Nigel Lange
CEO | Chief Executive Officer | - | 20-05-03 |
Douglas Cubbin
CHM | Chairman | - | 23-08-06 |
Director/Board Member | - | 23-07-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 0.007 | 0.00% | 12 870 397 |
24-04-17 | 0.007 | 0.00% | 1,080,830 |
24-04-16 | 0.007 | 0.00% | 355,639 |
24-04-15 | 0.007 | +16.67% | 6,571,232 |
24-04-12 | 0.006 | 0.00% | 10,807,190 |
Delayed Quote Australian S.E., April 18, 2024 at 02:10 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.22% | 10.14M | |
+28.73% | 676B | |
+23.58% | 554B | |
-7.63% | 349B | |
+14.81% | 318B | |
+7.19% | 291B | |
+2.96% | 210B | |
-0.41% | 204B | |
-10.02% | 194B | |
-11.99% | 144B |
- Stock Market
- Equities
- OSL Stock